Scholarlink

Purpose <p>This expert consensus aims to define how 2-deoxy-2-[18&#xa0;F]-fluoro-D-glucose ([¹⁸F]FDG) positron emission tomography/computed tomography (PET/CT) can be systematically integrated into clinical pathways for early identification of diffuse large B-cell lymphoma (DLBCL) patients who may benefit from chimeric antigen receptor T-cell (CAR-T) therapy. The main research question is how PET-derived parameters and timing can optimize risk stratification and guide timely referral for advanced therapies.</p> Methods <p>A multidisciplinary panel of nuclear medicine physicians and hematologists conducted a structured consensus process based on current literature, international guidelines, and expert discussion. Key clinical scenarios and statements were evaluated across multiple meetings to assess the role of PET/CT at baseline, interim, and end-of-treatment stages.</p> Results <p>PET/CT provides critical prognostic information throughout the disease course. Baseline quantitative metrics (e.g., metabolic tumor volume) improve risk stratification beyond conventional indices. Interim PET, particularly using Deauville score and the change in the maximum standardized uptake value, enables early identification of high-risk or refractory patients. End-of-treatment PET remains essential for response assessment and therapeutic decision-making. Standardization of acquisition, reporting, and interpretation is necessary to enhance reproducibility and clinical integration.</p> Conclusion <p>PET/CT should be considered a central biomarker in DLBCL management, enabling earlier identification of high-risk patients and facilitating timely CAR-T referral. Harmonized, multidisciplinary implementation is essential to optimize outcomes and improve access to potentially curative therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月26日

查看全文
  • Luca Guerra,
  • Domenico Albano,
  • Piera Angelillo,
  • Alice Di Rocco,
  • Mirko Farina,
  • Andrea Farolfi,
  • Vittoria Tarantino,
  • Carlo Visco,
  • Pier Luigi Zinzani

摘要

Purpose

This expert consensus aims to define how 2-deoxy-2-[18 F]-fluoro-D-glucose ([¹⁸F]FDG) positron emission tomography/computed tomography (PET/CT) can be systematically integrated into clinical pathways for early identification of diffuse large B-cell lymphoma (DLBCL) patients who may benefit from chimeric antigen receptor T-cell (CAR-T) therapy. The main research question is how PET-derived parameters and timing can optimize risk stratification and guide timely referral for advanced therapies.

Methods

A multidisciplinary panel of nuclear medicine physicians and hematologists conducted a structured consensus process based on current literature, international guidelines, and expert discussion. Key clinical scenarios and statements were evaluated across multiple meetings to assess the role of PET/CT at baseline, interim, and end-of-treatment stages.

Results

PET/CT provides critical prognostic information throughout the disease course. Baseline quantitative metrics (e.g., metabolic tumor volume) improve risk stratification beyond conventional indices. Interim PET, particularly using Deauville score and the change in the maximum standardized uptake value, enables early identification of high-risk or refractory patients. End-of-treatment PET remains essential for response assessment and therapeutic decision-making. Standardization of acquisition, reporting, and interpretation is necessary to enhance reproducibility and clinical integration.

Conclusion

PET/CT should be considered a central biomarker in DLBCL management, enabling earlier identification of high-risk patients and facilitating timely CAR-T referral. Harmonized, multidisciplinary implementation is essential to optimize outcomes and improve access to potentially curative therapies.